Search Results
Your search for c matches 3695 pages
Showing 1851 - 1900Nivolumab in Adjuvant Treatment of Melanoma
On December 20, 2017, nivolumab (Opdivo) was granted regular approval for adjuvant treatment of patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection.1,2 Nivolumab was previously approved for the treatment of patients with unresectable or...
Cooperative Group Trial Pioneer Dr. James F. Holland Dies at 92
ASCO AND THE ONCOLOGY COMMUNITY are deeply saddened by the loss of James F. Holland, MD, FASCO, who passed away on March 22, 2018. He was 92. Dr. Holland was a Distinguished Professor of Neoplastic Diseases in the Department of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at...
Massage Therapy for Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, reviews the current data on the use of massage to...
Updated International Myeloma Working Group Criteria: Diagnostic Challenges
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Landgren review the underlying data that shaped the updated International Myeloma Working Group (IMWG) diagnostic criteria for...
Pembrolizumab Monotherapy in NSCLC Meets Primary Endpoint in Phase III KEYNOTE-042 Study
On April 9, the phase III KEYNOTE-042 trial evaluating pembrolizumab (Keytruda) as monotherapy for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS). An ...
A Clinician’s Guide to Treating Patients With Glioblastoma
Glioblastoma, a grade 4 astrocytoma, is the most common and most aggressive form of primary brain tumors in adults. The most recent guidance on molecular profiling, diagnostic and prognostic factors, and treatments for newly diagnosed and recurrent diseases was described in the Journal of Oncology ...
Fine-Tuning Treatment in Myeloma and Leukemia
It is a difficult task to include every notable presentation from the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition. In addition to our more comprehensive coverage of the news from that meeting over the past several issues, below are summaries of additional key...
Expert Point of View: Marisa Weiss, MD
At a press conference where the findings by Chlebowski et al were presented, Marisa Weiss, MD, Founder and Chief Medical Officer of Breastcancer.org and Director of Radiation Oncology at Lankenau Medical Center in Philadelphia, commended this study. “We could set a goal of losing 5 pounds for our...
Expert Point of View: C. Kent Osborne, MD
C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, and moderator of a press conference where the EMBRACA findings were presented, shared his thoughts on the study. While a few months’ improvement in the risk of disease progression may seem...
Promise and Challenges of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: ZUMA-1 Trial Results
Advancing therapeutics and augmenting curability in diffuse large B-cell lymphoma (DLBCL) have been very challenging. Although many novel approaches have offered promise and continue to be developed, we have not yet identified a clearly superior approach to R-CHOP (rituximab [Rituxan],...
Nivolumab/Ipilimumab or Nivolumab Alone in Melanoma Brain Metastases
In an Australian phase II trial reported in The Lancet Oncology, Long et al found that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) and nivolumab alone showed intracranial activity in patients with melanoma brain metastases. Study Details In the open-label trial, 76 evaluable...
How to Respond to a Patient’s Discriminatory Request for a Different Clinician
Some patients may make discriminatory requests for a different clinician for their health care.1-5 These individuals may want to avoid treatment with clinicians of a certain race, religion, gender, sexual orientation, or national origin. Oncologists are not exempt from this type of patient...
Greater Understanding of Family Dynamics May Help Cancer Teams Guide, Support Patients
WHETHER THEY are parents themselves or dealing with their own parents, patients with cancer often look to their health-care team to help guide these relationships, but data on how best to help are lacking, according to two poster presentations at the 2018 American Psychosocial Oncology Society...
How Will ctDNA Assays Aid in Managing Breast Cancer?
CIRCULATING TUMOR DNA (ctDNA) assays are now commercially available for use in lung cancer and melanoma, where they can identify the presence of specific mutations that drive treatment selection. In breast cancer, ctDNA remains more of a research tool, but this is poised to change. At the 2018...
GU Symposium Focuses on Prognostic Model in Urothelial Cancer, Novel Therapies for Prostate and Kidney Cancers
THE 2018 GENITOURINARY Cancers Symposium hosted an international audience of oncologists and other stakeholders to hear about the latest advances in the field. We have included coverage of many of the top news stories from the meeting in previous issues of The ASCO Post. Here are summaries of a few ...
Phase II Study Shows Durvalumab Active in Patients With Recurrent or Metastatic Head and Neck Cancer
IN A POPULATION of heavily pretreated patients with recurrent or metastatic head and neck cancer and low or negative programmed cell death ligand 1 (PD-L1) expression, durvalumab (Imfinzi) monotherapy demonstrated an overall response rate of 9.2%, consistent with that of single-agent programmed...
Potent Anti-HER2 Agents on the Horizon
THANKS TO the efficacy of five approved anti-HER2 agents, patients with HER2-positive breast cancer have overall survival numbers that are as good as, or better than, their HER2-negative counterparts. With the next generation of anti-HER2 therapies in clinical trials, these outcomes may become even ...
A Tribute to Two Amazing Scientists
Dr. Collins is Director of the National Institutes of Health. Originally posted on March 19, 2018, to the National Institutes of Health (NIH) Director’s Blog (https://directorsblog. nih.gov). OVER THE PAST couple of weeks, we’ve lost two legendary scientists who made major contributions to our...
Extended Follow-up of Nivolumab Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma After Failure of Autologous HCT
As reported by Armand and colleagues in the Journal of Clinical Oncology, extended follow-up of the phase II CheckMate 205 trial continues to show benefits and good tolerability of nivolumab (Opdivo) treatment in relapsed or refractory classical Hodgkin lymphoma after failure of autologous ...
In Remembrance of James F. Holland, MD
The ASCO Post mourns the loss of ASCO Past President James F. Holland, MD, FASCO, on March 22, 2018. Dr. Holland was the Distinguished Professor of Neoplastic Diseases in the Department of Medicine at the Icahn School of Medicine at Mount Sinai in New York. His wife of many years, Jimmie C....
Venetoclax in Chronic Lymphocytic Leukemia Progressing After Ibrutinib
An interim analysis of a phase II trial reported by Jones et al in The Lancet Oncology indicates that venetoclax (Venclexta) produces a response in a high proportion of patients with chronic lymphocytic leukemia (CLL) progressing on or after ibrutinib (Imbruvica) treatment. John C. Byrd, MD, of...
Encourage Patients To Promptly Report Immunotherapy Side Effects
Physicians can be proactive in alerting patients to possible adverse effects of immunotherapy and in encouraging patients to report them. “It is important to emphasize that whenever a patient develops a new symptom, always considering that this might be an immune-related side effect. We need to...
Physician-Patient Partnership Is Key to Recognizing and Managing Side Effects of Immune Checkpoint Inhibitors
“Immunotherapy has a completely different side-effect profile than chemotherapy, and that has caught physicians off guard,” noted Drew Pardoll, MD, PhD, in an article published earlier this year in The Washington Post.1 Since then, efforts have moved forward on several fronts to bring physicians,...
AACR Welcomes New Leadership
The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR Board of Directors for the 2018–2021 term and four members to serve on the Nominating Committee for the 2018–2020 term. These new directors and committee members began their terms at...
James C. Wittig, MD, Joins Atlantic Health System Orthopedic Oncology Leadership Team
James C. Wittig, MD, has been appointed Chairman of the Department of Orthopedics at the Morristown Medical Center and Medical Director of Orthopedic Oncology within the Atlantic Health System. Dr. Wittig will be responsible for ensuring quality, academic excellence, and optimal operational...
IMpower150: Increased OS With Atezolizumab/Bevacizumab Plus Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower150 study met its coprimary endpoint of overall survival (OS) at interim analysis and showed that first-line treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) plus carboplatin and paclitaxel (chemotherapy) helped patients with advanced...
IMpower131 Study: Atezolizumab Plus Chemotherapy in Advanced Squamous NSCLC
On March 20, Genentech announced that the phase III IMpower131 study met its coprimary endpoint of progression-free survival (PFS) and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (carboplatin and nanopartical albumin-bound [nab]-paclitaxel [Abraxane])...
Venetoclax in Chronic Lymphocytic Leukemia Progressing After Ibrutinib
An interim analysis of a phase II trial reported by Jones et al in The Lancet Oncology indicates that venetoclax (Venclexta) produces a response in a high proportion of patients with chronic lymphocytic leukemia (CLL) progressing on or after ibrutinib (Imbruvica) treatment. John C. Byrd, MD, of The ...
Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer
“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions...
Raising Awareness of the Link Between Alcohol and Cancer
Prevention in Oncology is guest edited by Jennifer Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber Cancer...
EXPERT POINT OF VIEW: Kenneth C. Anderson, MD, and S. Vincent Rajkumar, MD
AT A PREMEETING webinar, American Society of Hematology then President Kenneth C. Anderson, MD, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, Boston, commented: “This study demonstrates this new treatment has good...
ASCO International: 2017 Year in Review
In late 2016, ASCO announced further expansion of its robust portfolio of international programs, and significant progress toward this expansion was achieved in 2017. All of these accomplishments reflect the hard work and commitment of many ASCO member volunteers, ASCO staff, and organizations...
Conquer Cancer Foundation Recognizes 70 Young Oncology Researchers’ Findings With Merit Awards
ASCO’s Conquer Cancer Foundation is pleased to announce the recipients of its Merit Awards in gastrointestinal cancers, clinical immuno-oncology, genitourinary cancers, and cancer survivorship. The following 70 researchers— oncology fellows and trainees honored for the quality and scientific merit...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
Studies Explore Colon Tumor Sidedness, Lung Radiation Dose in Esophageal Cancer, Pembrolizumab in Liver Cancer, and More
Along with full coverage of key presentations from the 2018 Gastrointestinal Cancers Symposium, The ASCO Post brings our readers this additional news roundup. Side Matters in Colon Cancer One of the studies included in the global IDEA trial, which compared 3 vs 6 months of adjuvant chemotherapy in ...
Circulating Tumor DNA Analysis: ASCO and CAP Joint Review
As reported in the Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine by Jason D. Merker, MD, PhD, of Stanford University School of Medicine, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a joint review on the status of...
AACR 2018: Chlamydia Infection May Be Associated With Increased Risk of Ovarian Cancer
An antibody that is present in the blood of women previously infected with the sexually transmitted infection chlamydia is associated with a doubling in ovarian cancer risk, according to data presented during a media preview for the 2018 American Association for Cancer Research (AACR) Annual...
AACR 2018: Underserved Populations Lack Information About Clinical Trials, Biobanking
People in Louisiana communities with cancer health disparities would be interested in participating in clinical trials or submitting samples to biobanks if provided information about these opportunities by a trusted physician—but physicians reported lacking appropriate information to give to...
FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML
On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...
Answers to Hematology Expert Review Questions
GUEST EDITORS: Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Bosutinib in Newly Diagnosed Chronic-Phase Philadelphia Chromosome–Positive Chronic Myeloid Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 19, 2017, bosutinib (Bosulif) was granted...
It Starts With a Discussion: ASCO Guideline on Interventions to Address Sexual Problems in People With Cancer
Dr. Katz is a certified sexuality counselor at CancerCare Manitoba, Canada. SEXUALITY AND SEXUAL functioning are important to cancer survivors, and considering the significant number of survivors, this is an issue that should not be ignored. In a survey of cancer survivors who had completed...
Interventions to Address Sexual Problems in People With Cancer: ASCO Clinical Practice Guideline Adaptation of CCO Guideline
AS REPORTED in the Journal of Clinical Oncology by Jeanne Carter, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a clinical practice guideline adaptation of the Cancer Care Ontario (CCO) guideline on interventions to address sexual problems in people with cancer.1 ...
Selected Abstracts From the San Antonio Breast Cancer Symposium
EACH YEAR, The ASCO Post asks Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer...
Acupuncture for the Management of Chemotherapy-Induced Peripheral Neuropathy
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, reviews the current data on the use of acupuncture...
Investigational Genomic Tool Identifies Consensus Molecular Subtype of Colon Tumor and May Predict Risk of Recurrence
AN INVESTIGATIONAL TOOL called ColotypeR classifies colon cancers by molecular subtype and creates a subtype-specific risk of recurrence, according to research. Developers of the tool say it will be able to guide treatment decisions. Colon cancer is highly heterogeneous in prognosis and response to ...
Team Wellness: Reflections From Front-Line Clinical Teams
In May 2017, I started to reflect on my own personal views of wellness and the importance of the team. Since that time, I have been fortunate to speak with members of front-line clinical teams from four different practices: Eric Tetzlaff, MSH, PA-C, and Michael Hall, MD, MS, of Fox Chase Cancer...
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
THE U.S. PREVENTIVE Services Task Force (USPSTF) recently published a final recommendation statement and evidence summary on screening for ovarian cancer. Based on its review of the evidence, the USPSTF recommends against screening for ovarian cancer in women who do not have any signs or symptoms...
Serum Bone Biomarkers in Early Breast Cancer and Risk of Bone Metastasis
In a study reported in the Journal of the National Cancer Institute, Brown et al found that the serum bone biomarkers P1NP, CTX, and 1-CTP showed good prognostic ability for bone metastasis in patients in the phase III AZURE (BIG01/04) trial of adjuvant zoledronic acid in early breast cancer....
